Position：Home >
Dehydroepiandrosterone (DHEA)-induced polycystic ovary syndrome (PCOS) model
Dehydroepiandrosterone (DHEA)-induced polycystic ovary syndrome (PCOS) model
Background
Dehydroepiandrosterone (DHEA) was administered subcutaneously to establish a polycystic ovary syndrome (PCOS) model.
Excess androgens interfere with follicular growth and maturation, leading to anovulation, accompanied by hyperinsulinemia and insulin resistance, which resembles human PCOS.
Materials and methods
- **Animals**: Female Sprague-Dawley rats, 21 days old
- **Model establishment**: Dehydroepiandrosterone (DHEA) was injected subcutaneously for 20 consecutive days to successfully establish a polycystic ovary syndrome (PCOS) model.
- **Evaluation index**: HE staining
- **Model establishment**: Dehydroepiandrosterone (DHEA) was injected subcutaneously for 20 consecutive days to successfully establish a polycystic ovary syndrome (PCOS) model.
- **Evaluation index**: HE staining
Test and verify
Ovarian HE staining
